Pfizer Inc. (NYSE:PFE) Given Average Rating of “Hold” by Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have earned an average recommendation of “Hold” from the nineteen research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $28.3529.

PFE has been the subject of several research analyst reports. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th.

Pfizer Trading Down 1.7%

NYSE PFE opened at $24.81 on Friday. The stock has a market capitalization of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer has a 52-week low of $20.92 and a 52-week high of $29.82. The firm has a 50-day moving average price of $24.86 and a 200 day moving average price of $24.13. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 91.49%.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter worth $28,000. North Capital Inc. purchased a new position in Pfizer during the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in Pfizer during the second quarter worth $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.